Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Tolvaptan, sold under the brand name Samsca among others, is an aquaretic drug that functions as a selective, competitive vasopressin receptor 2 (V2) antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration (FDA) on May 19, 2009, and is sold by Otsuka Pharmaceutical Co. under the trade name Samsca. Tolvaptan, as Jynarque, was granted approval for medical use in the United States in April 2018.
Read the full article on WikipediaAutosomal dominant polycystic kidney disease (ADPKD) Clinical criteria: Treatment Phase: Initial treatment Treatment criteria: Must be treated by a nephrologist. Patient must have an estimated glomerular filtration rate (eGFR) between 30 and 89 mL/min 1.73 m2 at the initiation of treatment with this drug for this condition, AND Patient must have or have had rapidly progressing disease at the time of initiation of this drug for this condition. Rapidly progressing disease is defined as either of the following: A decline in eGFR of greater than or equal to 5 mL/min/1.73 m2 within one year; OR An average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m2 per year over a five year period.
“12 hours (terminal)”
Working under the parallel aged-care framework? Aged-care equivalent →